CARA Cara Therapeutics Inc.

16.1
+0.05  (+0%)
Previous Close 16.05
Open 15.6
Price To Book 3.55
Market Cap 751,531,530
Shares 46,678,977
Volume 253,024
Short Ratio
Av. Daily Volume 833,823
Stock charts supplied by TradingView

NewsSee all news

  1. Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    STAMFORD, Conn., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by

  2. Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan

    STAMFORD, Conn., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by

  3. Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    STAMFORD, Conn., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by

  4. Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus

    – Met primary endpoint with statistically significant reduction in mean worst itching intensity NRS scores with 1 mg tablet strength vs. placebo after 12-week treatment period (p=0.018) –– Oral KORSUVA™ well-tolerated

  5. Cara Therapeutics to Present at November Investor Conferences

    STAMFORD, Conn., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released June 27, 2018. Company noted primary endpoint met but data mixed.
IV CR845
Acute pain
Phase 2b data released June 29, 2017 - trial failed.
CR845
Osteoarthritis (OA)
Phase 2 data due 2H 2020.
KORSUVA (CR845/difelikefalin) oral
Chronic Liver Disease-Associated Pruritus
Phase 3 data met primary endpoint - May 29, 2019.
KORSUVA (CR845/difelikefalin) injection - KALM-1
Chronic kidney disease (CKD) on hemodialysis (HD) with Moderate-to Severe Pruritus
Phase 3 enrolment to be completed 4Q 2019.
KORSUVA (CR845/difelikefalin) injection - KALM-2 global
Chronic kidney disease (CKD) on hemodialysis (HD) with Moderate-to Severe Pruritus
Phase 2 data met primary endpoint but secondary missed - December 3, 2019. Phase 3 trial to be initated 2H 2020.
KORSUVA (CR845/difelikefalin) oral
Stage 3-4 Chronic Kidney Disease-Associated Pruritus
Phase 2 interim analysis 2Q 2020. Top-line data 2H 2020.
KORSUVA (CR845/difelikefalin) oral
Atopic dermatitis patients with moderate-to-severe pruritus
Phase 2 data due 2020.
KORSUVA (CR845/difelikefalin) oral
Primary Biliary Cholangitis (PBC) - Pruritus

Latest News

  1. Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    STAMFORD, Conn., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by

  2. Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan

    STAMFORD, Conn., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by

  3. Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    STAMFORD, Conn., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by

  4. Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus

    – Met primary endpoint with statistically significant reduction in mean worst itching intensity NRS scores with 1 mg tablet strength vs. placebo after 12-week treatment period (p=0.018) –– Oral KORSUVA™ well-tolerated

  5. Cara Therapeutics to Present at November Investor Conferences

    STAMFORD, Conn., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by

  6. Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA™ Injection) KALM™-1 Phase 3 Trial Results in the New England Journal of Medicine

    - Treatment with KORSUVA Injection resulted in statistically significant reduction in pruritus intensity and improvement in itch-related quality of life measures vs placebo for both primary and secondary endpoints -

  7. Cara Therapeutics Reports Third Quarter 2019 Financial Results

    STAMFORD, Conn., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by

  8. Cara Therapeutics Announces Presentations at Kidney Week 2019

    STAMFORD, Conn., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by

  9. Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019

    STAMFORD, Conn., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by

  10. Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus

    - Patient enrollment increased approximately 20% to maintain >90% statistical power -  - Full trial enrollment expected in fourth quarter of 2019 - STAMFORD, Conn., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Cara

  11. Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    STAMFORD, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by

  12. SWK Holdings Corporation Files Application for Uplisting to NASDAQ Capital Market

    DALLAS, Sept. 3, 2019 /PRNewswire/ -- SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"), a life science focused specialty finance company, announced today that the Company has submitted its